0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What are the incidence, presenting characteristics, and change in incidence over time of angiosarcoma in the US?

          Findings

          This cross-sectional study of 19 289 patients with a new diagnosis of angiosarcoma found that the incidence of angiosarcoma is increasing among men and women in the US, with more than 1000 new cases diagnosed per year. This overall increase is associated with a higher incidence rate of secondary breast and chest wall angiosarcomas among women.

          Meaning

          These data increase awareness of a rare but highly morbid disease and highlight the need for monitoring and increased suspicion of angiosarcoma among patients at higher risk, such as women who have a prior history of breast cancer.

          Abstract

          Importance

          Angiosarcoma is an aggressive vascular malignant neoplasm presenting either as a primary or secondary cancer, often arising after radiotherapy or in the context of preexisting lymphedema. Comprehensive data describing its incidence and presentation patterns are needed.

          Objective

          To describe the incidence, presenting characteristics, and change over time of angiosarcoma in the US.

          Design, Setting, and Participants

          This retrospective cross-sectional study used data from the US Cancer Statistics (USCS) National Program of Cancer Registries–Surveillance, Epidemiology, and End Results Combined Database, which captures more than 99% of newly diagnosed cancers in the US. The study included all 19 289 patients in the US with a new diagnosis of angiosarcoma between 2001 and 2020 captured in the USCS database. Statistical analysis was performed from June to September 2023.

          Main Outcomes and Measures

          Incidence of angiosarcoma, demographics of patients with angiosarcoma, and extent of disease at presentation.

          Results

          The study included 19 289 patients (median age, 71 years [IQR, 59-80 years]; 10 506 women [54.5%]) with a new diagnosis of angiosarcoma. The US incidence of angiosarcoma doubled between 2001 (657 cases) and 2019 (1312 cases), reflecting both an increase in the adjusted incidence rate of 1.6% per year ( P = .001), to 3.3 cases per 1 000 000 person-years (95% CI, 3.1-3.5 cases per 1 000 000 person-years), and an increase in the population at risk. In 2020, the reported incidence rate (3.0 cases per 1 000 000 person-years) and cases of angiosarcoma (n = 1159) were modestly lower than in 2019. Overall, 72.3% of cases of angiosarcoma (n = 13 955) were cutaneous, subcutaneous, or breast angiosarcomas; 24.4% were visceral (n = 4701); and 3.3% were located in unknown or rare primary sites (n = 633). Secondary breast and chest wall angiosarcomas among women represented the largest contribution to increasing incidence. Among breast angiosarcomas, 99.2% (2684 of 2705) were in women and 71.9% (1944 of 2705) were secondary. A total of 80.4% of chest wall or thorax cases among women (1861 of 2316) were secondary vs 26.5% among men (112 of 422), and 63.9% of upper extremity cases among women (205 of 321) were secondary vs 26.8% (56 of 209) among men ( P = .001). Rates of secondary angiosarcoma in the abdomen and lower extremities were similar between men and women. The incidence rate of visceral angiosarcoma was also found to be increasing (1.5% per year; P = .001).

          Conclusions and Relevance

          This cross-sectional study describes angiosarcoma presentation patterns and incidence rates in the US over a 20-year period and shows that the number of cases in men and women increased, with the greatest increase among women with secondary angiosarcoma of the chest, breast, and upper extremity. These data increase awareness of a rare but highly morbid disease and highlight the need for improved early detection of angiosarcoma among patients at high risk, such as women with a history of breast cancer.

          Abstract

          This cross-sectional study uses data from the US Cancer Statistics National Program of Cancer Registries–Surveillance, Epidemiology, and End Results Combined Database to describe the incidence, presenting characteristics, and change over time of angiosarcoma in the US.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: not found
          • Article: not found

          Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

            To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival (OS). Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively. With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research

                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                12 April 2024
                April 2024
                12 April 2024
                : 7
                : 4
                : e246235
                Affiliations
                [1 ]Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington
                [2 ]Division of Medical Oncology, University of Washington, Seattle
                [3 ]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts
                [4 ]Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas
                [5 ]Department of Radiation Oncology, University of Washington, Seattle
                [6 ]Department of Surgery, University of Washington, Seattle
                [7 ]Department of Medical Oncology, Providence-Swedish Cancer Institute, Seattle, Washington
                [8 ]Department of Plastic and Reconstructive Surgery, Cleveland Clinic, Cleveland, Ohio
                [9 ]Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina
                Author notes
                Article Information
                Accepted for Publication: February 8, 2024.
                Published: April 12, 2024. doi:10.1001/jamanetworkopen.2024.6235
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2024 Wagner MJ et al. JAMA Network Open.
                Corresponding Author: Michael J. Wagner, MD, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 ( michael_wagner@ 123456dfci.harvard.edu ).
                Author Contributions: Drs Wagner and Paulson had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Wagner, Ravi, Schaub, Sharib, Mogal, Paulson.
                Acquisition, analysis, or interpretation of data: Wagner, Ravi, Schaub, Kim, Park, Tsai, Duarte-Bateman, Tufaro, Loggers, Cranmer, Chau, Hassett, Grilley-Olson, Paulson.
                Drafting of the manuscript: Wagner, Ravi, Schaub, Duarte-Bateman, Tufaro, Grilley-Olson, Paulson.
                Critical review of the manuscript for important intellectual content: All authors.
                Statistical analysis: Paulson.
                Obtained funding: Paulson.
                Administrative, technical, or material support: Kim, Mogal, Park, Tufaro, Paulson.
                Supervision: Ravi, Schaub, Mogal, Tufaro, Paulson.
                Conflict of Interest Disclosures: Dr Wagner reported receiving personal fees from Adaptimmune, Deciphera, Epizyme, Aadi Bioscience, and PharmaEssentia outside the submitted work. Dr Cranmer reported receiving grants to institution from Merck, Exelixis, Eli Lilly, Avacta, AADi Biosciences, Philogen, InhibRX, Zentalis, Boehringer Ingelheim; and personal fees from AADi Biosciences and Boehringer Ingelheim outside the submitted work. No other disclosures were reported.
                Funding/Support: Work supported in part through the Paul G Allen Research Center at Swedish Cancer Institute (Dr Paulson) and by support to the Sarcoma Oncology Program of the University of Washington from Curt and Elizabeth Anderson and grant P30CA015704 from the National Institutes of Health (Drs Wagner, Loggers, and Cranmer). Dr Cranmer was supported in part by the Curt and Elizabeth Anderson Endowed Professorship in Sarcoma Research, and by funding from Steve and Jane Urner.
                Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Data Sharing Statement: See Supplement 2.
                Article
                zoi240247
                10.1001/jamanetworkopen.2024.6235
                11015348
                38607625
                624d0697-dc54-417c-a8e1-39018228ad77
                Copyright 2024 Wagner MJ et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 16 November 2023
                : 8 February 2024
                Categories
                Research
                Original Investigation
                Online Only
                Oncology

                Comments

                Comment on this article